Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Blood (2012) 120 (21): 800.

https://doi.org/10.1182/blood.V120.21.800.800

Published: 2012

Journal Articles

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill Chang, MD, PhD, Vincent T Bicocca, Stephen Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. den Boer, C. M Zwaan, MD, PhD, Jason R. Gotlib, Michael W.N. Deininger, MD, Brian J. Druker

Blood (2008) 112 (11): 758.

https://doi.org/10.1182/blood.V112.11.758.758

Published: 2008

Journal Articles

Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

Thomas G.P. Bumm, Jeffrey W Tyner, PhD, Jutta Deininger, Marc Loriaux, Jonathan VanDyke, Brian J. Druker, Christopher J Burns, Emmanuelle Fantino3, Michael W.N. Deininger, MD

Blood (2008) 112 (11): 856.

https://doi.org/10.1182/blood.V112.11.856.856

Published: 2008

Journal Articles

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis

Jeffrey W Tyner, PhD, Heidi Erickson, Stephen Oh, MD, PhD, Jason R. Gotlib, Michael W.N. Deininger, MD, Brian J. Druker, Marc Loriaux, MD, PhD

Blood (2008) 112 (11): 2519.

https://doi.org/10.1182/blood.V112.11.2519.2519

Published: 2008

Journal Articles

Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.

Carlo Gambacorti-Passerini, Dong-Wook Kim, François-Xavier Mahon, Giuseppe Saglio, Fabrizio Pane, François Guilhot, Michael W.N. Deininger, Arnon Nagler, Alessandro Rambaldi, Enrica Morra, Laura Antolini, IL-Young Kweon, Josy Reiffers, Lucia Tornaghi, Maria Grazia Valsecchi

Blood (2008) 112 (11): 1099.

https://doi.org/10.1182/blood.V112.11.1099.1099

Published: 2008

Journal Articles

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Richard D. Press, MD, PhD, Stephanie G Willis, Jennifer Laudadio, Michael J. Mauro, MD, Michael W.N. Deininger, MD

Blood (2008) 112 (11): 1108.

https://doi.org/10.1182/blood.V112.11.1108.1108

Published: 2008

Journal Articles

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Michael W.N. Deininger, MD, Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, Jerald Radich

Blood (2008) 112 (11): 3236.

https://doi.org/10.1182/blood.V112.11.3236.3236

Published: 2008

Journal Articles

Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT

Amie S. Corbin, Thomas O’Hare, Brian J. Druker, Michael W.N. Deininger

Blood (2008) 112 (11): 190.

https://doi.org/10.1182/blood.V112.11.190.190

Published: 2008

Journal Articles

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

Oliver Pelz-Ackermann, Michael W.N. Deininger, PhD, Michael Cross, PhD, Kathrin Wildenberger, Rainer Krahl, PhD, Song-Yau Wang, MD, Haifa K. Al-Ali, MD, Dietger W. Niederwieser, MD, Thoralf Lange, MD

Blood (2007) 110 (11): 2918.

https://doi.org/10.1182/blood.V110.11.2918.2918

Published: 2007

Journal Articles

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy.

Jennifer Laudadio, MD, Michael W.N. Deininger, MD, Michael J. Mauro, MD, Brian J. Druker, MD, Richard D. Press, MD, PhD

Blood (2007) 110 (11): 1953.

https://doi.org/10.1182/blood.V110.11.1953.1953

Published: 2007

Journal Articles

RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients.

Jeffrey W. Tyner, PhD, Stephanie Willis, BS, Michael W.N. Deininger, MD, PhD, Brian J. Druker, MD

Blood (2007) 110 (11): 208.

https://doi.org/10.1182/blood.V110.11.208.208

Published: 2007

Journal Articles

Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission.

Thomas G.P. Bumm, MD, Amy Hanlon Newell, PhD, Jay Oost, Jonathan VanDyke, Susan B. Olson, PhD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2007) 110 (11): 36.

https://doi.org/10.1182/blood.V110.11.36.36

Published: 2007

Journal Articles

Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles.

Blood (2007) 110 (11): 206.

https://doi.org/10.1182/blood.V110.11.206.206

Published: 2007

Journal Articles

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

Thomas G.P. Bumm, MD, Jonathan VanDyke, Marc Loriaux, MD, PhD, Carolyn Gendron, Lisa G. Wood, PhD, RN, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2007) 110 (11): 675.

https://doi.org/10.1182/blood.V110.11.675.675

Published: 2007

Journal Articles

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

Thomas O’Hare, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Matthew J. Wong, Caitlyn A. Smith, Amie S. Corbin, Sean Buchanan, PhD, Katayoun A. Jessen, PhD, Crystal Tang, Kevin Holme, PhD, Stephen K. Burley, MD, PhD, Michael W.N. Deininger, MD, PhD

Blood (2006) 108 (11): 1373.

https://doi.org/10.1182/blood.V108.11.1373.1373

Published: 2006

Journal Articles

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Anupriya Agarwal, PhD, Thomas G.P. Bumm, MD, Amie Corbin, Thomas O’Hare, PhD, Marc Loriaux, MD, PhD, Stephanie G. Willis, Jutta Deininger, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2006) 108 (11): 742.

https://doi.org/10.1182/blood.V108.11.742.742

Published: 2006

Journal Articles

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib.

M. MacPartlin, T. O’Hare, T. Bumm, V. Goss, K. Lee, A. Corbin, E.A. Stoffregen, C. Smith, K. Johnson, E. Moseson, I. Griswold, L. Wood, R. Polakiewicz, Brian J. Druker, Michael W.N. Deininger

Blood (2006) 108 (11): 4796.

https://doi.org/10.1182/blood.V108.11.4796.4796

Published: 2006

Journal Articles

Monitoring Imatinib Resistance with a “Polony” Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).

Valentina Nardi, MD, Tal Raz, PhD, Xinyu Chao, Catherine J. Wu, MD, Richard Stone, MD, Ilene Galinsky, RN, NP, Martha Wadleigh, MD, Michael W.N. Deininger, MD, PhD, George Church, PhD, Jun Zhu, PhD, George Q. Daley, MD, PhD

Blood (2006) 108 (11): 837.

https://doi.org/10.1182/blood.V108.11.837.837

Published: 2006

Journal Articles

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

Richard D. Press, MD, PhD, Stephanie Willis, Carole Rempfer, Michael J. Mauro, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD

Blood (2006) 108 (11): 2152.

https://doi.org/10.1182/blood.V108.11.2152.2152

Published: 2006

Journal Articles

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Lucy C. Crossman, MD, Thomas O’Hare, PhD, Thoralf Lange, MD, Stephanie G. Willis, Eric P. Stoffregen, Amie S. Corbin, Stephen G. O’Brien, MD, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD, Peter G. Middleton, PhD, Michael W.N. Deininger, MD, PhD

Blood (2005) 106 (11): 1530.

https://doi.org/10.1182/blood.V106.11.1530.1530

Published: 2005

NARROW

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis

Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients.

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy.

RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients.

Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission.

Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles.

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib.

Monitoring Imatinib Resistance with a “Polony” Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only